Compare SSB & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSB | HALO |
|---|---|---|
| Founded | 1933 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.1B |
| IPO Year | 2008 | 2001 |
| Metric | SSB | HALO |
|---|---|---|
| Price | $108.89 | $82.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $118.00 | $78.64 |
| AVG Volume (30 Days) | 819.5K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 12.91 | N/A |
| EPS | ★ 4.64 | 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $10.07 | $28.24 |
| Revenue Next Year | $6.51 | $12.56 |
| P/E Ratio | ★ $23.53 | $68.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.48 | $61.23 |
| 52 Week High | $110.47 | $84.44 |
| Indicator | SSB | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 69.83 | 68.80 |
| Support Level | $92.40 | $67.63 |
| Resistance Level | N/A | $84.44 |
| Average True Range (ATR) | 1.98 | 1.93 |
| MACD | 0.43 | 0.08 |
| Stochastic Oscillator | 90.87 | 97.52 |
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time, and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.